Buparlisib & Paclitaxel
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Head and Neck Cancer
Conditions
Head and Neck Cancer
Trial Timeline
Dec 12, 2020 → Nov 2, 2025
NCT ID
NCT04338399About Buparlisib & Paclitaxel
Buparlisib & Paclitaxel is a phase 3 stage product being developed by Adlai Nortye for Head and Neck Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04338399. Target conditions include Head and Neck Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04338399 | Phase 3 | Completed |
Competing Products
20 competing products in Head and Neck Cancer